121 related articles for article (PubMed ID: 9443624)
1. Antiangiogenic and antiproliferative activity of suramin analogues.
Gagliardi AR; Kassack M; Kreimeyer A; Muller G; Nickel P; Collins DC
Cancer Chemother Pharmacol; 1998; 41(2):117-24. PubMed ID: 9443624
[TBL] [Abstract][Full Text] [Related]
2. The sulfonic acid polymers PAMPS [poly(2-acrylamido-2-methyl-1-propanesulfonic acid)] and related analogues are highly potent inhibitors of angiogenesis.
Liekens S; Neyts J; Degrève B; De Clercq E
Oncol Res; 1997; 9(4):173-81. PubMed ID: 9268988
[TBL] [Abstract][Full Text] [Related]
3. Antiproliferative and angiostatic activity of suramin analogues.
Firsching A; Nickel P; Mora P; Allolio B
Cancer Res; 1995 Nov; 55(21):4957-61. PubMed ID: 7585536
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of heparanase activity and heparanase-induced angiogenesis by suramin analogues.
Marchetti D; Reiland J; Erwin B; Roy M
Int J Cancer; 2003 Mar; 104(2):167-74. PubMed ID: 12569571
[TBL] [Abstract][Full Text] [Related]
5. Suramin inhibits bFGF-induced endothelial cell proliferation and angiogenesis in the chick chorioallantoic membrane.
Danesi R; Del Bianchi S; Soldani P; Campagni A; La Rocca RV; Myers CE; Paparelli A; Del Tacca M
Br J Cancer; 1993 Nov; 68(5):932-8. PubMed ID: 7692920
[TBL] [Abstract][Full Text] [Related]
6. Suramin, an anticancer and angiosuppressive agent, inhibits endothelial cell binding of basic fibroblast growth factor, migration, proliferation, and induction of urokinase-type plasminogen activator.
Takano S; Gately S; Neville ME; Herblin WF; Gross JL; Engelhard H; Perricone M; Eidsvoog K; Brem S
Cancer Res; 1994 May; 54(10):2654-60. PubMed ID: 7513254
[TBL] [Abstract][Full Text] [Related]
7. Angiostatic effects of suramin analogs in vitro.
Firsching-Hauck A; Nickel P; Yahya C; Wandt C; Kulik R; Simon N; Zink M; Nehls V; Allolio B
Anticancer Drugs; 2000 Feb; 11(2):69-77. PubMed ID: 10789588
[TBL] [Abstract][Full Text] [Related]
8. A structure-activity analysis of antagonism of the growth factor and angiogenic activity of basic fibroblast growth factor by suramin and related polyanions.
Braddock PS; Hu DE; Fan TP; Stratford IJ; Harris AL; Bicknell R
Br J Cancer; 1994 May; 69(5):890-8. PubMed ID: 7514028
[TBL] [Abstract][Full Text] [Related]
9. Suramin is a potent inhibitor of vascular endothelial growth factor. A contribution to the molecular basis of its antiangiogenic action.
Waltenberger J; Mayr U; Frank H; Hombach V
J Mol Cell Cardiol; 1996 Jul; 28(7):1523-9. PubMed ID: 8841939
[TBL] [Abstract][Full Text] [Related]
10. Capillary plexus development in the day five to day six chick chorioallantoic membrane is inhibited by cytochalasin D and suramin.
Melkonian G; Munoz N; Chung J; Tong C; Marr R; Talbot P
J Exp Zool; 2002 Feb; 292(3):241-54. PubMed ID: 11857458
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and binding mode of heterocyclic analogues of suramin inhibiting the human basic fibroblast growth factor.
Manetti F; Cappello V; Botta M; Corelli F; Mongelli N; Biasoli G; Borgia AL; Ciomei M
Bioorg Med Chem; 1998 Jul; 6(7):947-58. PubMed ID: 9730230
[TBL] [Abstract][Full Text] [Related]
12. Suramin analogues with a 2-phenylbenzimidazole moiety as partial structure; potential anti HIV- and angiostatic drugs, 2: Sulfanilic acid-, benzenedisulfonic acid-, and naphthalenetrisulfonic acid analogues.
Kreimeyer A; Müller G; Kassack M; Nickel P; Gagliardi AR
Arch Pharm (Weinheim); 1998 Mar; 331(3):97-103. PubMed ID: 9557135
[TBL] [Abstract][Full Text] [Related]
13. Eriochrome Black T, structurally related to suramin, inhibits angiogenesis and tumor growth in vivo.
Morris AD; Léonce S; Guilbaud N; Tucker GC; Pérez V; Jan M; Cordi AA; Pierré A; Atassi G
Anticancer Drugs; 1997 Sep; 8(8):746-55. PubMed ID: 9396618
[TBL] [Abstract][Full Text] [Related]
14. Rhodostomin, a snake venom disintegrin, inhibits angiogenesis elicited by basic fibroblast growth factor and suppresses tumor growth by a selective alpha(v)beta(3) blockade of endothelial cells.
Yeh CH; Peng HC; Yang RS; Huang TF
Mol Pharmacol; 2001 May; 59(5):1333-42. PubMed ID: 11306719
[TBL] [Abstract][Full Text] [Related]
15. Different ways to antiangiogenesis by angiostatin and suramin, and quantitation of angiostatin-induced antiangiogenesis.
Bahramsoltani M; Plendl J
APMIS; 2007 Jan; 115(1):30-46. PubMed ID: 17223849
[TBL] [Abstract][Full Text] [Related]
16. Novel function of ascorbic acid as an angiostatic factor.
Ashino H; Shimamura M; Nakajima H; Dombou M; Kawanaka S; Oikawa T; Iwaguchi T; Kawashima S
Angiogenesis; 2003; 6(4):259-69. PubMed ID: 15166494
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of receptor/G protein coupling by suramin analogues.
Beindl W; Mitterauer T; Hohenegger M; Ijzerman AP; Nanoff C; Freissmuth M
Mol Pharmacol; 1996 Aug; 50(2):415-23. PubMed ID: 8700151
[TBL] [Abstract][Full Text] [Related]
18. Histidine-proline-rich glycoprotein has potent antiangiogenic activity mediated through the histidine-proline-rich domain.
Juarez JC; Guan X; Shipulina NV; Plunkett ML; Parry GC; Shaw DE; Zhang JC; Rabbani SA; McCrae KR; Mazar AP; Morgan WT; Doñate F
Cancer Res; 2002 Sep; 62(18):5344-50. PubMed ID: 12235005
[TBL] [Abstract][Full Text] [Related]
19. Neridronate inhibits angiogenesis in vitro and in vivo.
Ribatti D; Nico B; Mangieri D; Maruotti N; Longo V; Vacca A; Cantatore FP
Clin Rheumatol; 2007 Jul; 26(7):1094-8. PubMed ID: 17106617
[TBL] [Abstract][Full Text] [Related]
20. Goniodomin A, an antifungal polyether macrolide, exhibits antiangiogenic activities via inhibition of actin reorganization in endothelial cells.
Abe M; Inoue D; Matsunaga K; Ohizumi Y; Ueda H; Asano T; Murakami M; Sato Y
J Cell Physiol; 2002 Jan; 190(1):109-16. PubMed ID: 11807817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
